Nebivolol
Nebivolol is a highly beta-1-selective beta-blocker with an additional nitric-oxide-mediated vasodilating action. It is licensed for hypertension and, in Europe, heart failure. PED users favour it over older beta-blockers for on-cycle blood-pressure and heart-rate control because its vasodilation and metabolic neutrality tend to spare libido, lipids and exercise tolerance.
01 Overview
Nebivolol blocks beta-1 adrenergic receptors to slow heart rate and reduce cardiac output, while stimulating endothelial nitric-oxide release to relax blood vessels. This dual action lowers blood pressure with less of the peripheral vasoconstriction, fatigue and adverse lipid or glucose effects associated with non-selective beta-blockers.
Among PED users it is used to manage the elevated blood pressure and resting heart rate that accompany many cycles, and sometimes to blunt stimulant-driven tachycardia. Its comparatively favourable side-effect profile — including less impact on erectile function than traditional beta-blockers — is the main reason it is chosen. As with any beta-blocker, abrupt discontinuation can cause rebound and it can mask hypoglycaemia and reduce peak exercise capacity.
02 Mechanism
Highly beta-1-selective adrenoceptor antagonist that also promotes endothelial nitric-oxide-mediated vasodilation, lowering heart rate, cardiac output and vascular resistance.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| On-cycle BP / heart-rate control | 2.5–10 mg/day | Oral | Titrated to blood pressure and resting heart rate. |
| Hypertension (label) | 5–40 mg/day | Oral | Usual start 5 mg once daily, titrated. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Lowered BP and heart rateReduces blood pressure and resting heart rate with vasodilation, well documented in hypertension trials. | dose-dependent | Clinical | |
| Metabolically neutral profileLess adverse effect on lipids, glucose and erectile function than non-selective beta-blockers. | vs older beta-blockers | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Bradycardia / fatigueExcessively slow heart rate, tiredness and reduced exercise tolerance. | Moderate | Common | Clinical | |
| Rebound on abrupt cessationSudden stopping can cause rebound tachycardia and raised blood pressure. | Moderate | Uncommon | Clinical |